scholarly journals Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts

2019 ◽  
Vol 94 (5) ◽  
pp. 512-521 ◽  
Author(s):  
Xiao‐Su Zhao ◽  
Yan‐Rong Liu ◽  
Lan‐Ping Xu ◽  
Yu Wang ◽  
Xiao‐Hui Zhang ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Disease Status ◽  
Multiparametric Flow Cytometry ◽  
Minimal Residual

scholarly journals The Clinical Significance of Minimal Residual Disease Detected By Multiparametric Flow Cytometry in Acute Leukemia

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5261-5261
Author(s):  
Fen Huang ◽  
Hui Jing ◽  
Zhengshan Yi ◽  
Xiaolei Wei ◽  
Zhongxin Zheng ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Acute Leukemia ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Intensive Therapy ◽  
Remission Induction ◽  
Hematopoietic Stem ◽  
Multiparametric Flow Cytometry ◽  
The Relationship ◽  
Minimal Residual

Abstract Purpose Minimal residual disease (MRD) detected by multiparametric flow cytometry is an important method for predicting relapse. According to the dynamic changes of MRD, through the first clinical treatment to prevent relapse in patients with elevated MRD levels. Method We retrospectively analyze dynamic level of MRD of 75 patients with acute leukemia in our department of hematology from January 2011 to June 2013. According to the retrospective data, to analyze the expression of LAIP and discuss the relationship between changes of MRD and prognosis. Result In this study there were 75 patients, including 20 patients with acute lymphocytic leukemia (ALL) and 55 patients with acute myeloid leukemia (AML). The specific LAIP were detected in 49 patients with AML, and the cross lineage and non-synchronous expression were majority. In cross lineage expression, detected frequency of CD45/CD34/CD33/CD13/CD56 was highest, accounted for 67.3% (33/49). In non-synchronous expression, CD45/CD34/CD117/CD33/CD64 accounted for 57.1% (28/49). In 20 patients with ALL, there were 16 patients with B-ALL and 4 patients with T-ALL. The specific LAIP were detected in all of the patients. In patients with B-ALL, detected frequency of CD45/CD19/CD22/CD10/CD13 was highest, accounting for 43.8% (7/16). In abnormal quantity of antigens, CD45/CD19/CD22/CD10/CD38 was the most common type, accounting for 50%. The abnormal expression of CD7/TDT was detected in four patients with T-ALL. In monitoring period 7 patients relapsed. We analyzed the relationship between the clinical data and replase. The results showed that level of peripheral hemoglobin at diagnosis and the times of remission induction were significantly associated with replase (P=0.021 and P=0.017, respectively). To analyze the relationship between change of MRD and prognosis, the results showed that 0.05% as the threshold was significantly related with recurrence. 20 patients of persistent MRD≥0.05% had significant differences with 28 patients of persistent MRD<0.05% in replase free survival (P=0.005). Conclusion It has important significance to predict relapse in patients with acute leukemia by detecting minimal residual disease. Patients of MRD ≥ 0.05% should receive early intensive therapy or hematopoietic stem cell transplantation. Even patients without relapse, it should be closely monitor dynamic levels of MRD and highly vigilant extramedullary relapse. Disclosures No relevant conflicts of interest to declare.

Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry

2017 ◽  
Vol 30 (Suppl 2) ◽  
pp. 2S21-2S28
Author(s):  
Lucie Říhová ◽  
Pavla Všianská ◽  
Renata Bezděková ◽  
Romana Králová ◽  
Miroslav Penka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Disease Assessment ◽  
Multiparametric Flow Cytometry ◽  
Minimal Residual

scholarly journals Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis

2020 ◽  
Vol 4 (5) ◽  
pp. 880-884 ◽  
Author(s):  
Andrew Staron ◽  
Eric J. Burks ◽  
John C. Lee ◽  
Shayna Sarosiek ◽  
J. Mark Sloan ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Minimal Residual Disease ◽  
Plasma Cell ◽  
Residual Disease ◽  
Complete Response ◽  
Cardiac Response ◽  
Al Amyloidosis ◽  
Multiparametric Flow Cytometry ◽  
Organ Response ◽  
Minimal Residual

Abstract Despite achieving a hematologic complete response after treatment, many patients with AL amyloidosis do not attain recovery of organ function and/or experience hematologic relapse. A persistent plasma cell clone producing amyloidogenic light chains at levels below the detection threshold of traditional serologic methods is hypothesized to impede organ response in some patients. Assessment of minimal residual disease (MRD) may therefore have clinical importance as a more stringent treatment response tool for patients in a hematologic complete response. We used 2-tube, 10-color combination multiparametric flow cytometry to assess for MRD at a minimum sensitivity of 1 in 105 nucleated cells. Of 65 patients in hematologic complete response, 36 (55%) were found to have a residual clonal plasma cell population in the bone marrow. Comparing the MRD-negative and MRD-positive groups, renal response was observed in 88% vs 64% (P = .06), cardiac response in 75% vs 59% (P = .45), and any organ response in 90% vs 75% (P = .20) of patients. Depth of organ response as measured by the percent decrease in 24-hour proteinuria and brain natriuretic peptide was 96% vs 91% (P = .16) and 55% vs 46% (P = .66), respectively. These data suggest a possible correlation between MRD negativity and higher probability of organ response after treatment in AL amyloidosis. Future prospective studies with a larger cohort are needed to determine the clinical relevance of these improvements. This trial was registered at www.clinicaltrials.gov as #NCT00898235.

scholarly journals Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country

2017 ◽  
Vol 1 (Suppl) ◽  
pp. 80-83
Author(s):  
Lorena Lobo de Figueiredo-Pontes ◽  
Maria Isabel Ayrosa Madeira ◽  
Luisa Koury Corrêa de Araujo ◽  
Priscila Santos Scheucher ◽  
Fabíola Traina ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Acute Myeloid Leukemia ◽  
Minimal Residual Disease ◽  
Developing Country ◽  
Myeloid Leukemia ◽  
Residual Disease ◽  
Multiparametric Flow Cytometry ◽  
Minimal Residual ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document